Original ArticlesSafety and Clinical Outcomes of Hospital in the HomeSriskandarajah, Shanthy MSc∗; Ritchie, Brett MBBS†; Eaton, Vaughn MClinPharm‡; Sluggett, Janet K. PhD§,∥; Hobbs, Jodie G. BEng∗; Daniel, Santhosh MBBS¶,∗∗; Reynolds, Karen J. PhD∗Author Information From the ∗Medical Device Research Institute, College of Science and Engineering, Flinders University, Adelaide, South Australia †Infectious Diseases Department, Women’s and Children’s Hospital, North Adelaide, South Australia ‡SA Pharmacy, Southern Adelaide Local Health Network, Adelaide §CPIE Pharmacy Services, Findon, South Australia ∥Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria ¶Infectious Diseases, Flinders Medical Centre, Adelaide, South Australia ∗∗College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia. Correspondence: Karen Reynolds, PhD, Medical Device Research Institute, Flinders University, GPO Box 2100, Adelaide 5001, South Australia (e-mail: [email protected]). This trial is part of a wider project approved and funded by a Premier’s Research and Industry Fund grant (provided by the South Australian Government Department of Further Education, Employment, Science and Technology), entitled “Increased Safety and Efficacy of Hospital in the Home Services Through Improved Drug Infusion Devices,” which aims to inform the future development of ambulatory infusion devices. J.K.S. is a shareholder in Infusion Innovations Pty Ltd. Infusion Innovations Pty Ltd was established to attract grant funding and conduct further studies in the field, and Infusion Innovations Pty Ltd has filed the infusion device patent application PCT/AU2017/050019. The other authors disclose no conflict of interest. Journal of Patient Safety: June 2020 - Volume 16 - Issue 2 - p 123-129 doi: 10.1097/PTS.0000000000000617 Buy Metrics Abstract Objectives The aim of the study was to evaluate clinical outcomes and adverse events (AEs) experienced by patients treated within the Hospital in the Home (HITH) service of a major metropolitan hospital in South Australia. Methods A retrospective case note audit of 100 HITH episodes among adults who received continuous intravenous antimicrobial therapy via an elastomeric or electronic infusion device was undertaken. Age- and sex-adjusted binomial logistic regression analyses were undertaken to identify factors associated with major and minor AEs. Results Of the 100 patients included, 71 were male and the mean (SD) patient age was 62.8 (17.19) years. Elastomeric infusion devices were used for 98 patients. The mean (SD) HITH treatment duration was 20.1 (11.9) days. Overall, 130 AEs were documented for 72 patients (72%), of whom 12 patients experienced a major AE and 68 patients experienced a minor AE. There were 45 occasions among 23 patients where an infusion administered through an elastomeric device did not run to completion. Fifteen patients were readmitted to hospital. Minor AEs were more likely among people with more vascular line days (adjusted odds ratio [aOR] = 1.05; 95% confidence interval (CI) = 1.01–1.10 per day increase) and females (aOR = 4.43; 95% CI = 1.14–17.17). An increased number of vascular line days was associated with an increased likelihood of an incomplete infusion (aOR = 1.05; 95% CI = 1.01–1.09). Hospital readmission was more likely with increasing age (aOR = 1.06; 95% CI = 1.01–1.11 per year increase). Conclusions Adverse events need to be monitored carefully when HITH treatment is provided for extended periods. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.